

Table SI. Primer and siRNA sequences used in this study.

Name	Sequence (5'-3')
BCAT1 overexpression primer	
BCAT1-F	ATGAAGGATTGCAGTAACGGA
BCAT1-R	TCAGGATAGCACAATTGTCCAG
siRNA sequences	
Control siRNA	TTCTCCGAACGTGTCACGT
BCAT1 siRNA #1 (Best)	GAGCTCTTAGAGTGTATTCAACA
BCAT1 siRNA #2	GGCATTTCGAGGAGTAGATAATA
BCAT1 siRNA #3	ATGTGTTACAAGAGTGATTGTTT
q-PCR sequences	
BCAT2- primer-F	CGCTGAATGGTGTTCCTGCC
BCAT2- primer-R	CAGCAACTGCTTCATGGTGATCG
BCKDK - primer-F	GCCACAATGGAGAGTCACCTAG
BCKDK - primer-R	CTTTGTGAGCGATTCCTCCACC
BCKDHB - primer-F	TGCACTGTTGGCTTGCGAGACA
BCKDHB - primer-R	TTCCGCAATGGCAGTAGCTCCA
β -actin - primer-F	CACCATTGGCAATGAGCGGTTT
β -actin - primer-R	AGGTCTTTGCGGATGTCCACGT

BCAT1, BCAA transaminase 1; BCKDK, branched-chain α -ketoacid dehydrogenase kinase; siRNA, small interfering RNA; qPCR, quantitative PCR; F, forward; R, reverse.

Table SII. Top 10 core targets of astragaloside IV against breast cancer ranked by degree centrality.

Target name	Degree
HSP90AA1	46
BCAT1	46
AKT1	40
EGFR	39
PIK3CA	36
TNF	31
BCL2	31
ESR1	27
JAK2	26
PIK3CB	25

BCAT1, BCAA transaminase 1; BCKDK, branched-chain α -ketoacid dehydrogenase kinase.